Literature DB >> 144789

Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

E K Perry, P H Gibson, G Blessed, R H Perry, B E Tomlinson.   

Abstract

Reductions in 2 neurotransmitter synthesizing enzymes in brain, glutamic acid decarboxylase (GAD) and choline acetyltransferase (CAT), have been found in dementias of different origins, including senile dementia (Alzheimer type). Significant reductions in cerebral GAD have also been found in depression (unipolar). The GAD reductions did not generally appear to be localised in any specific region of the brain examined. However, the reduction of CAT in the hippocampus, relative to reductions in other areas examined, was substantially greater in the brains with Alzheimer-type changes. GAD and CAT activities in normal brains were examined for the effects of some variable factors inherent in necropsy biochemical measurements. These factors included: (i) age; (ii) agonal status; (iii) time of death, and (iv) delay in tissue sampling; and GAD was found to be significantly influenced by (ii), (iii) and (iv) and CAT by (i), (iii) and (iv). None of these factors accounted for the total alterations in the enzyme activities of the mentally abnormal brains. The results indicate that reductions in cerebral GAD require to be interpreted with caution in view of the sensitivity of this enzyme to premortem status but that reductions in cerebral CAT may be a more reliable index of pathological change in senile (Alzheimer-type) dementia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 144789     DOI: 10.1016/0022-510x(77)90073-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  96 in total

1.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

2.  NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease.

Authors:  J W Unger; W Lange
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 3.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

4.  Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.

Authors:  E D London; M J Ball; S B Waller
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

5.  Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

Authors:  Benjamin Kolisnyk; Mohammed A Al-Onaizi; Pedro H F Hirata; Monica S Guzman; Simona Nikolova; Shahar Barbash; Hermona Soreq; Robert Bartha; Marco A M Prado; Vania F Prado
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

6.  A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.

Authors:  A Little; R Levy; P Chuaqui-Kidd; D Hand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

7.  Choline acetyltransferase and acetylcholinesterase abnormalities in senile dementia: importance of biochemical measurements in human post-mortem brain specimens.

Authors:  S Sorbi; P Antuono; L Amaducci
Journal:  Ital J Neurol Sci       Date:  1980-03

Review 8.  Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.

Authors:  R Quirion
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

Review 9.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

10.  Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13C] and [2-13C] glucose.

Authors:  Graeme F Mason; Kitt Falk Petersen; Robin A de Graaf; Gerald I Shulman; Douglas L Rothman
Journal:  J Neurochem       Date:  2006-10-31       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.